Palbociclib

Catalog No. A14427

Palbociclib是一种吡啶并嘧啶衍生的细胞周期蛋白依赖性激酶(CDK)抑制剂,具有潜在的抗肿瘤活性。
  • Kana Nakatani, .et al. Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells, Int J Hematol, 2020, Oct 17 PMID: 33068248
  • Ryohei Ogata, .et al. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells, Breast Cancer, 2020, Aug 28 PMID: 32860163
  • Kishino E, .et al. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells, Breast Cancer, 2019, Dec 10 PMID: 31823286
  • Hidemasa Matsuo, .et al. Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia, Blood Adv, 2018, Nov 13; 2(21): 2879-2889 PMID: 30381403
  • Zhihong Li, .et al. Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3, J Med Chem, 2014, Apr 24;57(8):3430-49 PMID: 24641103
Catalog Num A14427
M. Wt 447.53
Formula C24H29N7O2
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 571190-30-2
Synonyms PD0332991, PD-0332991, PD 0332991
SMILES CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
Palbociclib是一种吡啶并嘧啶衍生的细胞周期蛋白依赖性激酶(CDK)抑制剂,具有潜在的抗肿瘤活性。
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 22.34 mL 111.72 mL 223.45 mL
0.5 mM 4.47 mL 22.34 mL 44.69 mL
1 mM 2.23 mL 11.17 mL 22.34 mL
5 mM 0.45 mL 2.23 mL 4.47 mL

*The above data is based on the productmolecular weight 447.53. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.